In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Sarepta Therapeutics Inc’s stock clocked out at $18.8, up 4.79% from its previous closing price of $17.94. In other words, the price has increased by $4.79 from its previous closing price. On the day, 7.55 million shares were traded. SRPT stock price reached its highest trading level at $18.85 during the session, while it also had its lowest trading level at $17.68.
Ratios:
To gain a deeper understanding of SRPT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.81 and its Current Ratio is at 2.89. In the meantime, Its Debt-to-Equity ratio is 1.00 whereas as Long-Term Debt/Eq ratio is at 1.00.
On July 29, 2025, JP Morgan Upgraded its rating to Neutral which previously was Underweight but kept the price unchanged to $24.
Barclays Upgraded its Underweight to Equal Weight on July 29, 2025, while the target price for the stock was maintained at $22.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 12 ’25 when Nicaise Claude sold 2,491 shares for $99.64 per share. The transaction valued at 248,203 led to the insider holds 27,812 shares of the business.
Nicaise Claude bought 2,491 shares of SRPT for $248,226 on Mar 12 ’25. On Dec 12 ’24, another insider, Wigzell Hans Lennart Rudolf, who serves as the Director of the company, sold 10,500 shares for $124.84 each. As a result, the insider received 1,310,820 and left with 22,840 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SRPT now has a Market Capitalization of 1837011840 and an Enterprise Value of 2401166592. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.74 while its Price-to-Book (P/B) ratio in mrq is 1.35. Its current Enterprise Value per Revenue stands at 0.968 whereas that against EBITDA is 59.809.
Stock Price History:
The Beta on a monthly basis for SRPT is 0.49, which has changed by -0.85873157 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, SRPT has reached a high of $144.22, while it has fallen to a 52-week low of $10.41. The 50-Day Moving Average of the stock is -13.32%, while the 200-Day Moving Average is calculated to be -75.49%.
Shares Statistics:
It appears that SRPT traded 11.42M shares on average per day over the past three months and 14876030 shares per day over the past ten days. A total of 97.71M shares are outstanding, with a floating share count of 92.91M. Insiders hold about 4.91% of the company’s shares, while institutions hold 97.78% stake in the company. Shares short for SRPT as of 1753920000 were 20945080 with a Short Ratio of 1.83, compared to 1751241600 on 14683653. Therefore, it implies a Short% of Shares Outstanding of 20945080 and a Short% of Float of 25.14.
Earnings Estimates
The company has 12.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is -$0.36, with high estimates of $1.63 and low estimates of -$2.02.
Analysts are recommending an EPS of between $4.26 and -$4.2 for the fiscal current year, implying an average EPS of -$1.62. EPS for the following year is $3.36, with 16.0 analysts recommending between $6.39 and -$1.89.
Revenue Estimates
In the current quarter, 20 analysts expect revenue to total $342.03M. It ranges from a high estimate of $511.14M to a low estimate of $213.19M. As of the current estimate, Sarepta Therapeutics Inc’s year-ago sales were $467.17MFor the next quarter, 20 analysts are estimating revenue of $336.77M. There is a high estimate of $488.58M for the next quarter, whereas the lowest estimate is $113.19M.
A total of 24 analysts have provided revenue estimates for SRPT’s current fiscal year. The highest revenue estimate was $2.36B, while the lowest revenue estimate was $1.68B, resulting in an average revenue estimate of $2.04B. In the same quarter a year ago, actual revenue was $1.9BBased on 23 analysts’ estimates, the company’s revenue will be $1.58B in the next fiscal year. The high estimate is $2.25B and the low estimate is $984.59M.
